Skip to content
★ Sign in to follow
AR
Total declarations
65
Company
1
▲ Purchases (10 ops.)
€76k
▼ Sales (31 ops.)
€8.9M

Latest filing published 07 Apr 2011 for HAEMONETICS CORP, €7,219.

Insider track record

Disclosed buys
10
Disclosed sells
31
Signal history

No signal scores available.

Closed purchases

Market purchases
10
Positive at T+90
63%
Median T+90
+1.7%

Based on 8 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 08 Nov 2010 · 5844 days ago · €4,920
    -0.7%
    Entry US$29.39 · Close at T+365 US$29.17
  • Filed 04 May 2010 · 6032 days ago · €11k
    +19.6%
    Entry US$28.11 · Close at T+365 US$33.63
  • Filed 03 Nov 2009 · 6214 days ago · €2,606
    +4.8%
    Entry US$27.63 · Close at T+365 US$28.95
  • Filed 05 May 2009 · 6396 days ago · €11k
    +9.2%
    Entry US$25.52 · Close at T+365 US$27.87
  • Filed 04 Nov 2008 · 6578 days ago · €5,259
    -1.1%
    Entry US$27.89 · Close at T+365 US$27.59

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Alicia R. Lopez: trading record in brief

This profile gathers the share dealings of Alicia R. Lopez in Haemonetics Corp. We count 65 filings; the first trade dates from 24 March 2006 and the latest from 5 April 2011.

Market trades split into 10 purchases (€76k) and 31 sales (€8.9M). On balance, insiders were net sellers of €8.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants and 15 option exercises.

A typical purchase (the median) is worth €7,342. For 8 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 63% of cases, with a median move of +1.7%. These figures describe past trades and do not predict future prices.

The record was last updated on 7 April 2011 with a transaction (€7,219) in Haemonetics Corp. The latest purchase dates back some time: it was published 5,844 days ago, on 8 November 2010. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Alicia R. Lopez

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations61 total
  • ●
    VP, Corporate AffairsExecutivesHaemonetics Corp
    10,264 USD0SEC
    155 shares@ US$66.22Common StockSEC:0000313143-11-000016:0
  • ●
    VP, Corporate AffairsExecutivesHaemonetics Corp
    513,077 USD0SEC
    8,047 shares@ US$63.76Common StockSEC:0000313143-10-000115:0
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    389,814 USD0SEC
    7,146 shares@ US$54.55Common StockSEC:0000313143-10-000108:0
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    435,263 USD0SEC
    7,146 shares@ US$60.91Common StockSEC:0000313143-10-000108:1
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    699,550 USD0SEC
    17,000 shares@ US$41.15Common StockSEC:0000313143-10-000108:2
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    1M USD0SEC
    17,000 shares@ US$60.91Common StockSEC:0000313143-10-000108:3
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    633,200 USD0SEC
    20,000 shares@ US$31.66Common StockSEC:0000313143-10-000108:4
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    1M USD0SEC
    20,000 shares@ US$60.91Common StockSEC:0000313143-10-000108:5
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    563,550 USD0SEC
    17,000 shares@ US$33.15Common StockSEC:0000313143-10-000108:6
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    542,312 USD0SEC
    10,619 shares@ US$51.07Common StockSEC:0000313143-10-000108:8
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    646,803 USD0SEC
    10,619 shares@ US$60.91Common StockSEC:0000313143-10-000108:9
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    785,649 USD0SEC
    14,891 shares@ US$52.76Common StockSEC:0000313143-10-000108:10
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    907,011 USD0SEC
    14,891 shares@ US$60.91Common StockSEC:0000313143-10-000108:11
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    261,100 USD0SEC
    10,000 shares@ US$26.11Common StockSEC:0000313143-10-000108:12
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    609,100 USD0SEC
    10,000 shares@ US$60.91Common StockSEC:0000313143-10-000108:13
  • ▲
    VP, Corporate AffairsExecutivesHaemonetics Corp
    6,951 USD0SEC
    150 shares@ US$46.34Common StockSEC:0000313143-10-000098:0
    Canonical exit: 2 Feb 2011 (T+90)
  • ▲
    VP, Corporate AffairsExecutivesHaemonetics Corp
    14,533 USD0SEC
    318 shares@ US$45.70Common StockSEC:0000313143-10-000033:0
    Canonical exit: 29 Jul 2010 (T+90)
  • ◇
    VP, Corporate AffairsExecutivesHaemonetics Corp
    248,963 USD0SEC
    10,867 shares@ US$22.91Common StockSEC:0000313143-10-000016:0
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    652,020 USD0SEC
    10,867 shares@ US$60.00Common StockSEC:0000313143-10-000016:1
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    1M USD0SEC
    20,000 shares@ US$60.00Common StockSEC:0000313143-10-000016:2
  • ▲
    VP, Corporate AffairsExecutivesHaemonetics Corp
    3,839 USD0SEC
    87 shares@ US$44.13Common StockSEC:0000313143-09-000086:0
    Canonical exit: 28 Jan 2010 (T+90)
  • ◆
    VP, Corporate AffairsExecutivesHaemonetics Corp
    0SEC
    483 shares0Common StockSEC:0000313143-09-000068:0
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    3,905 USD0SEC
    72 shares@ US$54.24Common StockSEC:0000313143-09-000062:0
  • ▼
    VP, Corporate AffairsExecutivesHaemonetics Corp
    3,871 USD0SEC
    71 shares@ US$54.52Common StockSEC:0000313143-09-000062:1
  • ▲
    VP, Corporate AffairsExecutivesHaemonetics Corp
    15,230 USD0SEC
    347 shares@ US$43.89Common StockSEC:0000313143-09-000029:0
    Canonical exit: 30 Jul 2009 (T+90)

25 of 61 declarations